BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//BioCatalystFeed//bcf//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:BioCatalystFeed NTHI catalysts
X-WR-CALDESC:Scheduling/reference data from public records\; dates can move
 . Not investment\, legal or medical advice.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:92563cdae9f8ffdf3b7c@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:NTHI P1/P2 readout (est.): Safety and Efficacy Study in Recurrent o
 r Progressive Grade III or IV IDH1 Mutated Glioma
DESCRIPTION:Safety and Efficacy Study in Recurrent or Progressive Grade III
  or IV IDH1 Mutated Glioma\nNCT02704858 | PHASE1/PHASE2 | ACTIVE_NOT_RECRU
 ITING | sponsor: Neonc Technologies\, Inc.\nPrimary completion date (ESTIM
 ATED)\; top-line results usually follow later.\nTicker NTHI (confidence 0.
 9)\nSource: https://clinicaltrials.gov/study/NCT02704858\nScheduling/refer
 ence data from public records\; dates can move. Not investment\, legal or 
 medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT02704858
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:0ac1a280ed5fe4425e95@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20261230
DTEND;VALUE=DATE:20261231
SUMMARY:NTHI P2 readout (est.): NEO100 and High-Grade Meningioma
DESCRIPTION:NEO100 and High-Grade Meningioma\nNCT05023018 | PHASE2 | RECRUI
 TING | sponsor: Neonc Technologies\, Inc.\nPrimary completion date (ESTIMA
 TED)\; top-line results usually follow later.\nTicker NTHI (confidence 0.9
 )\nSource: https://clinicaltrials.gov/study/NCT05023018\nScheduling/refere
 nce data from public records\; dates can move. Not investment\, legal or m
 edical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT05023018
CATEGORIES:readout,ESTIMATED
END:VEVENT
END:VCALENDAR
